ClinicalTrials.gg
CompletedNCT03323385Updated Jun 18, 2023Results posted

Evaluation of Preoperative N1539 in Colorectal Surgery

A Phase 3 interventional study of N1539 and Placebo in Pain, Postoperative, sponsored by Baudax Bio. Completed at 10 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Baudax Bio · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing meloxicam in Pain, Postoperative — 2 open to participants now, 3 under way, none of them phase 3. Meloxicam · Pain, Postoperative.

Enrollment
18th of 24
57 · median 112
Started
2017
with 4 others
Phase 3
9 of 24
none open now
Registered
10th of 24
by date
Lead sponsor
7 of 24
Baudax Bio

Among the 24 studies testing meloxicam in Pain, Postoperative, this one is the 18th largest by enrollment, is one of 5 that started in 2017, is one of 9 in phase 3, and was the 10th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 24 studies testing meloxicam in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About meloxicam

Meloxicam: first FDA approval 2000 (MOBIC), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing meloxicam in Pain, Postoperative, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of preoperative dosing of N1539 30 mg in subjects undergoing colorectal surgery, including clinical laboratory tests, wound healing evaluation, incidence of anastomotic leaks, and incidence of Adverse Events (AEs) and Serious AEs (SAEs).

03

Conditions studied

  • Pain, Postoperative

Keywords

  • Colorectal surgery
  • Pain
  • Analgesia
  • N1539
  • Phase 3b
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily provide written .
  • Be planned to undergo primary (no repeat procedures) open or laparoscopic colorectal surgery (laparoscopic expected to require a ≥ 5 cm incision) with bowel resection and/or anastomosis.
  • category 1, 2, or 3.
  • Female subjects not pregnant or planning/attempting to become pregnant, not lactating; or commits to the use of an acceptable form of for the duration of the study.
  • Have a \<40 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Have a known allergy or to any study treatment.
  • Planned surgical procedure includes a resection beyond the peritoneal reflection, is related to an acute bout of diverticulitis, or is associated with an emergency procedure.
  • Have a history of myocardial infarction within the preceding 12 months.
  • Have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant condition that would preclude participation.
  • Have active or recent (within 6 months) gastrointestinal ulceration or bleeding, with exception of events related to an ulcerative colitis diagnosis.
  • Have a known bleeding disorder which may be worsened with the administration of an NSAID.
  • Be currently receiving treatment with oral meloxicam (Mobic®) or another NSAID within 48 hours prior to surgery.
  • Have previously received N1539/IV meloxicam or received any product within 30 days before dosing with study medication.
  • Have undergone or be expected to undergo radiation therapy, chemotherapy, or other biological therapy for cancer treatment, within 60 days prior to screening through last follow-up.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    N1539 30 mg

    N1539 (meloxicam injection for IV use) 30 mg every 24 hours

    Drug: N1539

  • Placebo comparator
    IV Placebo

    IV Placebo every 24 hours

    Drug: Placebo

Interventions

  • DrugN1539

    Once Daily

    Also known as: Intravenous meloxicam

  • DrugPlacebo

    Once Daily

    Also known as: Intravenous placebo

06

What researchers measure

Primary outcomes

  1. Evaluation of Safety and Tolerability - Number of Subjects With an AE

    Evaluate the incidence of adverse events in subjects receiving N1539 30 mg vs. placebo prior to colorectal surgery

    Time frame: Up to 30 days

07

Results

Posted Jun 18, 2023

Participant flow

Participant flow — Overall Study
MilestoneN1539 30 mgIV Placebo
Started2730
Dosed2728
Completed2627
Not completed13
Withdrew: Withdrawal by subject12
Withdrew: Noncompliance01

Outcome measures

PrimaryEvaluation of Safety and Tolerability - Number of Subjects With an AE

Evaluate the incidence of adverse events in subjects receiving N1539 30 mg vs. placebo prior to colorectal surgery

Time frame:
Up to 30 days
Reported as:
Number · participants
Evaluation of Safety and Tolerability - Number of Subjects With an AE
participantsN1539 30 mgIV Placebo
Evaluation of Safety and Tolerability - Number of Subjects With an AE2326

Adverse events

Collected over 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
N1539 30 mg0/27 (0%)3/27 (11.1%)11/27 (40.7%)
IV Placebo0/28 (0%)4/28 (14.3%)17/28 (60.7%)
Most frequent serious events
Most frequent serious events
EventN1539 30 mgIV Placebo
IleusGastrointestinal disorders1/272/28
Incision site cellulitisInfections and infestations1/270/28
Wound dehiscenceInjury, poisoning and procedural complications1/270/28
Urinary retentionRenal and urinary disorders1/270/28
HypoglycaemiaMetabolism and nutrition disorders0/271/28
Paranasal sinus benign neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/271/28
Most frequent other events
Most frequent other events
EventN1539 30 mgIV Placebo
NauseaGastrointestinal disorders9/2714/28
VomitingGastrointestinal disorders5/275/28
IleusGastrointestinal disorders1/275/28
Urinary retentionRenal and urinary disorders2/270/28
ConstipationGastrointestinal disorders1/272/28

Baseline characteristics

All randomized subjects

Age, Continuous
Age, Continuous(years)N1539 30 mgIV PlaceboTotal
Mean58.8 ± 11.1860.6 ± 11.0759.7 ± 11.06
Sex: Female, Male
Sex: Female, Male(Participants)N1539 30 mgIV PlaceboTotal
Female121123
Male151732
Race (NIH/OMB)
Race (NIH/OMB)(Participants)N1539 30 mgIV PlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American459
White222345
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)N1539 30 mgIV PlaceboTotal
United States272855
08

Study locations

10 sites
  • Research Center
    Florence, Alabama 35630, United States
  • Research Center
    Mobile, Alabama 36605, United States
  • Research Center
    Miami, Florida 33136, United States
  • Research Center
    Tampa, Florida 33606, United States
  • Research Center
    Metairie, Louisiana 70006, United States
  • Research Center
    Jackson, Mississippi 39202, United States
  • Research Center
    Cleveland, Ohio 44111, United States
  • Research Center
    Cleveland, Ohio 44195, United States
  • Research Center
    Columbus, Ohio 43210, United States
  • Research Center
    Philadelphia, Pennsylvania 19140, United States
09

References and documents

Publications

  • Silinsky JD, Marcet JE, Anupindi VR, Karkare SU, Shah DR, Mack RJ, McCallum SW, Du W, Freyer A, Black LK. Preoperative intravenous meloxicam for moderate-to-severe pain in the immediate post-operative period: a Phase IIIb randomized clinical trial in 55 patients undergoing primary open or laparoscopic colorectal surgery with bowel resection and/or anastomosis. Pain Manag. 2021 Jan;11(1):9-21. doi: 10.2217/pmt-2020-0061. Epub 2020 Oct 23. PubMed 33094682 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Sep 2018, 11 months.

Results were first posted in Jun 2023, 4 years 8 months after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 11 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2017
First posted
Oct 27, 2017
StartActual
Oct 24, 2017
Primary completionActual
Sep 26, 2018
CompletionActual
Sep 26, 2018
Results first posted
Jun 18, 2023
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03323385
Lead sponsor
Baudax Bio
Responsible party
Sponsor
First posted
Oct 27, 2017
Start date
Oct 24, 2017
Primary completion
Sep 26, 2018
Completion
Sep 26, 2018
Results posted
Jun 18, 2023
Last update
Jun 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion